Response to letter to the editor: Safety of transcranial direct current stimulation: Evidence based update 2016

Marom Bikson*,
Department of Biomedical Engineering, The City College of New York, New York, NY, USA

Pnina Grossman,
Department of Biomedical Engineering, The City College of New York, New York, NY, USA

Adantchede Louis Zannou,
Department of Biomedical Engineering, The City College of New York, New York, NY, USA

Greg Kronberg,
Department of Biomedical Engineering, The City College of New York, New York, NY, USA

Dennis Truong,
Department of Biomedical Engineering, The City College of New York, New York, NY, USA

Paulo Boggio,
Cognitive Neuroscience Laboratory and Developmental Disorders Program, Center for Health and Biological Sciences, Mackenzie Presbyterian University, Sao Paulo, Brazil

Andre R. Brunoni,
Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, Laboratory of Neurosciences (LIM-27), University of São Paulo, São Paulo, Brazil

Leigh Charvet,
NYU MS Comprehensive Care Center, Department of Neurology, New York University School of Medicine, New York, NY, USA

Felipe Fregni,
Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Brita Fritsch,
Department of Neurology, University Medical Center, Freiburg, Germany

BrainLinks-BrainTools Cluster of Excellence, University of Freiburg, Germany

Bernadette Gillick,
Department of Physical Medicine and Rehabilitation, University of Minnesota Medical School, Minneapolis, MN, USA

Roy H. Hamilton,
Laboratory for Cognition and Neural Stimulation, University of Pennsylvania, Philadelphia, PA, USA

*Corresponding author: bikson@ccny.cuny.edu (M. Bikson).
Center for Cognitive Neuroscience, University of Pennsylvania, Philadelphia, PA, USA
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA

Benjamin M. Hampstead,
Mental Health Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA

Adam Kirton,
Departments of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Helena Knotkova,
MJHS Institute for Innovation in Palliative Care, New York, NY, USA
Department of Social and Family Medicine, Albert Einstein College of Medicine, The Bronx, NY, USA

David Liebetanz,
Department of Clinical Neurophysiology, University Medical Center, Georg-August-University, Goettingen 37075, Germany

Anli Liu,
NYU Comprehensive Epilepsy Center, New York University School of Medicine, New York, NY, USA

Colleen Loo,
Psychiatry, Black Dog Institute, Clinical Academic, St George Hospital, University of New South Wales, Sydney, Australia

Michael A. Nitsche,
Department of Clinical Neurophysiology, University Medical Center, Georg-August-University, Goettingen 37075, Germany
Leibniz Research Centre for Working Environment and Human Factors at the TU Dortmund, Dortmund, Germany
Department of Neurology, University Medical Hospital Bergmannsheil, Bochum, Germany

Janine Reis,
Department of Neurology, University Medical Center, Freiburg, Germany
BrainLinks-BrainTools Cluster of Excellence, University of Freiburg, Germany

Jessica D. Richardson,
Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Department of Communication Sciences & Disorders, The University of South Carolina, Columbia, SC, USA
Department of Speech and Hearing Sciences, The University of New Mexico, Albuquerque, NM, USA
Alexander Rotenberg,  
Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA  

Pediatric Neuromodulation Program, Division of Epilepsy and Neurophysiology, Department of Neurology, Children’s Hospital Boston, Harvard Medical School, Boston, MA, USA  

Peter E. Turkeltaub, and  
Department of Neurology, Georgetown University, Washington, DC, USA  
Research Division, MedStar National Rehabilitation Hospital, Washington, DC, USA  

Adam J. Woods  
Center for Cognitive Aging and Memory, Institute on Aging, Department of Aging and Geriatric Research, McKnight Brain Institute, University of Florida, Gainesville, FL, USA

Dear Editor

We respond to concerns raised by Godinho et al. about the Bikson et al. tDCS safety review [1]. As stated in the opening sentence, our report provided an update “based on published Serious Adverse Effects in human trials and irreversible brain damage in animal models”. Further, we carefully defined the scope of the review, “In this review, tDCS safety indicates the absence of a Serious Adverse Effect including brain tissue injury related to tDCS application.” We developed precise criteria for a Serious Adverse Effect. A systematic review of all adverse events, including minor side effects that may affect the acceptability and tolerability of tDCS (as suggested by Godhino et al.) was outside the scope of our review, and addressed elsewhere including recently by our coauthors [2].

Adverse event underreporting occurs in most medical fields. We dedicated our assessment to published reports specifically of Serious Adverse Events, assuming reporting a Serious Adverse Event (e.g. hospitalization) is more reliable than mild well-known tDCS side effects (e.g. itching). Speculation regarding unpublished adverse events was not incorporated into our evidence-based approach. Causality was explicit to our definition of Serious Adverse Effect namely: “based on scientific judgment is determined to be caused or aggravated by the application of direct current to the head.”

Exact methodology to estimate the volume of tDCS sessions was indicated in the relevant section, but safety considerations were based on the complete tDCS literature as assessed by authors with domain expertise. We underscore that our conclusions are derived from, and are explicitly limited to, stated definitions -such that the discourse by Godinho et al. does not affect the validity of our methodology. To the extent that Godinho et al. do not provide evidence for a Serious Adverse Effect by tDCS, the review conclusion is unchanged.


Brain Stimul. Author manuscript; available in PMC 2018 May 30.
Michael A. Nitsche, Janine Reis, Jessica D. Richardson, Alexander Rotenberg, Peter Turkeltaub, Adam Woods.

References
